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Background.The role of prolactin (PRL) on tissue injury and repairmechanisms inmultiple sclerosis (MS) remains unclear.The aim
of this work was to investigate the relationship between PRL plasma levels and brain damage as measured by magnetic resonance
imaging (MRI). Methods. We employed a chemiluminescence immunoassay for measuring plasma levels of PRL. We used a 1.5 T
scanner to acquire images and Jim 4.0 and SIENAX software to analyse them. Results. We included 106 women with relapsing
remitting (RR)MS and stable disease in the last twomonths.Therewas no difference in PRL plasma levels between patients with and
without gadolinium enhancement onMRI. PRL plasma levels correlatedwithwhitematter volume (WMV) (rho = 0.284,𝑝 = 0.014)
but not with grey matter volume (GMV). Moreover, PRL levels predicted changes in WMV (Beta: 984, 𝑝 = 0.034). Conclusions.
Our data of a positive association between PRL serum levels and WMV support the role of PRL in promoting myelin repair as
documented in animal models of demyelination. The lack of an increase of PRL in the presence of gadolinium enhancement,
contrasts with the view considering this hormone as an immune-stimulating and detrimental factor in the inflammatory process
associated with MS.
1. Background
In addition to its primary roles in mammary gland develop-
ment, as well as the initiation and maintenance of lactation,
prolactin (PRL) is believed to be involved in a number of
physiological roles, including immune system modulation
promoting B cell autoreactivity and cell proliferation promot-
ing myelin repair [1, 2].
However, the role of PRL in tissue injury and repair
mechanisms related tomultiple sclerosis (MS) is still debated.
Prolactin (PRL) has long been proposed as an immune-
stimulating and detrimental factor in autoimmune disorders.
However, recent findings have challenged this common view,
showing that PRL does not play a crucial role in the devel-
opment of experimental autoimmune encephalomyelitis, the
animal model for multiple sclerosis (MS), and even protects
against adjuvant inducedmodel of rheumatoid arthritis [3, 4].
Some authors reported elevated PRL level among female MS
patients compared with controls and patients with Clinically
Isolated Syndrome (CIS) [5] while some others failed to
demonstrate this association [6]. A relationship between
PRL and MS relapses has been also proposed: higher serum
levels of PRL were found in patients with RRMS during
relapse and in patients with optic neuritis when compared to
healthy controls [7, 8]. Furthermore, there is evidence that a
reduction in number of gadolinium- (Gd-) enhancing lesions
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by a single intravenous infusion of methylprednisolone is
correlated with a parallel decline of PRL [9].
Recently, experimental evidences suggest a role of PRL in
endogenous repair of white matter damage. PRL signalling
is both necessary and sufficient for the pregnancy-induced
increase in oligodendrocyte precursor cells proliferation,
and, most strikingly, PRL treatments mimic the regenerative
effects of pregnancy and promote white matter repair and
remyelination [2].
The aim of the present study is to investigate the role
of PRL on damage and repair in MS; with this objective
we analysed the relationship between PRL plasma levels and
brain MRI data in a cohort of female patients.
2. Methods
2.1. Population. For this study, MS patients [10] regularly
attending the MS Centre of S. Andrea Hospital in Rome were
consecutively recruited before starting a first-line disease
modifying treatment (DMT) (within a month before starting
DMT). Eligibility criteria included women in childbearing
age with RRMS aged between 18 and 45 years; an entry
score on the Expanded Disability Status Scale (EDSS) [11]
≤5.0 and at least two relapses in the previous 48 months or
one relapse during the preceding 12 months; no relapses or
steroids intake in the previous 60 days. Exclusion criteria
included pathology of the reproductive system; pregnancy
or interruption of pregnancy in the previous 12 months;
prior immunosuppressive therapy; interferon-beta or any
experimental drugs before study entry; glatiramer acetate;
and consumption of oral contraceptives in the prior three
months.The study protocol was approved by the local ethical
committee; each patient provided written informed consent
before any study-related procedure.
2.2. MRI Acquisition and Analysis. Patients underwent a
brain MRI with a 1.5-Tesla Philips scanner.TheMRI protocol
included proton-density and T2-weighted fast spin-echo
sequences, fluid-attenuated inversion recovery sequence, and
T1-weighted images obtained before and five minutes after
intravenous injection of 0.1mmol/kg of gadolinium (Gd).
Acquisitions were obtained on the axial plane and consisted
of 46 contiguous, 3mm thick slices. MRI images were
transferred to the Neuroscience MRI Laboratory of Sapienza
University of Rome for analysis. Hyperintense lesion volumes
on T2-weighted images and hypointense lesion volumes
on T1-weighted postcontrast images were identified and
quantified using a semiautomated method (Jim 4.0, Xinapse
System, Leicester, UK) to obtain T2 lesion load (T2-LL), T1-
hypointense lesion load (T1-LL) calculated on the postcon-
trast images (i.e., black holes), and Gd-enhancing lesion load
(Gd-LL). Volumes of white matter (WM) and grey matter
(GM), normalised for subject head size, were estimated with
SIENAX [12], part of FSL package [13].
2.3. Hormonal Level Dosage. Blood samples were collected
during the follicular phase of menstrual cycle. Before
the analysis, blood samples were stored in a refrigerator
controlled at a stable temperature of −80∘C. The chemilumi-
nescence immunoassay method was used to obtain plasma
levels of PRL for each patient.
2.4. Statistical Analysis. Data are presented as mean (stan-
dard deviation) or median (range), as appropriate. Dif-
ferences between patients with and without gadolinium-
enhancing lesion, defined as Active Patients (APs) and
Nonactive Patients (NPs), respectively, were assessed with
independent samples 𝑡-test and with Mann-Whitney test as
appropriate. Relationship between PRL and cerebral volumes
was assessed with partial correlation. To control for the possi-
ble influence of age, disease duration, T2-LL, and presence of
gadolinium enhancement, on cerebral volumes, these factors
were added as correcting variables. Predictors of WM and
GM volumes were assessed by means of a multivariate linear
regression model in a stepwise fashion (for inclusion: 𝐹 ≥ 1,
𝑝 ≤ 0.005; for exclusion: 𝐹 < 1, 𝑝 > 1). Each model included
demographic, clinical, radiological, and hormonal charac-
teristics as covariates. All 𝑝 values less than 0.05 in either
direction were considered as significant. Statistical analyses
were carried out by a PC version of Statistical Package for
Social Sciences, version 17.0 (IBM SPSS, Chicago, IL, USA).
3. Results
We included 106 womenwith amean (SD) age of 30 (6) years,
mean MS duration of 3.3 (3.2) years, and median EDSS of 1.5
(range 0–4.5). Mean PRL level was 12.4 (7) ng/mL, only five
patients presented PRL levels above laboratory normal range
(5–25 ng/mL) (LNR), and they did not present significant
differences in clinical and MRI features compared with the
others (data not shown). Sixty-four patients (60%) presented
Gd enhancement on MRI. Table 1 shows demographical and
MRI data of patients according to the presence of enhance-
ment onMRI.We found significant lower volume ofWMand
higher T2-LL and T1-LL in patients with Gd enhancement
than in patients without Gd enhancement. No difference
was found in PRL plasma levels between the two groups
(Table 1). We did not find any correlation between PRL and
number of Gd-enhancing lesions or Gd-LL in patients with
Gd enhancement even after correcting for age and disease
duration (𝑝 = 0.948 and 𝑝 = 0.734, resp.).
Figure 1 shows a significant positive correlation between
PRL plasma values and WM volume for the entire study
population (rho = 0.209, 𝑝 = 0.033). PRL plasma levels
did not correlate with any other clinical or MRI parameters
including GW volume (rho = −0.013, 𝑝 = 0.893).
Predictors for WM volume were PRL level (Beta: 1094,
𝑝 = 0.02) and EDSS (Beta: −8742, 𝑝 = 0.015). Predictors for
GM volume were T1-LL (Beta: −6.9, 𝑝 < 0.001), age (Beta:
−2979, 𝑝 < 0.001), and disease duration (Beta: −2416, 𝑝 =
0.04) (Table 2).
4. Discussion
The role of PRL on exacerbating disease or promoting
recovery inMS is still debated. Despite the increasing number
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Table 1: Demographical and MRI data of patients according to
the presence of Gd enhancement on MRI. All values are expressed
as median (range) except for age and disease duration that are
expressed as mean (SD).
Patients with Gd
enhancement on
MRI
𝑁 = 64
Patients without Gd
enhancement on
MRI
𝑁 = 42
𝑝
Age (years) 29 (6) 31 (6) 0.52
Disease
duration (years) 2.9 (2.3) 3.6 (3.7) 0.22
Number of
relapses in the
previous 2 years
1.5 (0–6) 1 (0–3) 0.32
EDSS 1.5 (0–4.5) 1.5 (0–4.5) 0.47
PRL (ng/mL) 11.7 (6.2) 13.4 (8) 0.23
T2-LL (mm3) 8516 (59930–1490) 3508 (48675–378) <0.001
T1-LL (mm3) 1458 (15399–45) 477 (15501–0) 0.006
WM volume
(mm3)
726,750
(659,865–823,248)
750,682
(685,150–820,434) 0.004
GM volume
(mm3)
810,380
(667344–897,404)
815,054
(694,489–929,6557) 0.231
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Figure 1: Relationship between PRL plasma levels andWMvolume.
of studies performed in vitro and on animal models, clinical
studies are still poor and include a low number of patients
[14]. In this panorama, our study is the first to correlate PRL
levels with MRI data from a large cohort of MS patients and
adds some relevant piece of information.
First, our data do not support a correlation between
PRL and disease subclinical activity: we did not find an
increase of PRL levels in patients with active disease as
resulting from the presence of Gd enhancement on brain
MRI scan. Moshirzadeh et al. reported higher PRL serum
levels in patients with MS during relapse than in healthy
control supporting the hypothesis that patients with RRMS
are in a hyperprolactinemic state [7]. However, differently
fromMoshirzadeh et al., we studied patients clinically stable;
therefore, we could not rule out an increase of PRL during
clinical exacerbations as previously reported [7, 8]. Our
Table 2: Significant predictors of WM volume and GM volume.
Predictors Beta 95% CI 𝑝
White matter volume
EDSS −8742 −15727; −1757 0.015
PRL 1094 173; 2014 0.02
Gray matter volume
Age −2979 −4205; −1754 <0.001
Disease duration −2416 −4717; −115 0.04
T1-LL −6.9 −9.3; 4.5 <0.001
data seems to be in contrast with even previous report
from Yamasaki et al. who showed an increase in serum
PRL level during acute relapse involving optic nerve [8].
This apparent discrepancy can be explained by differences
in the characteristics of populations included in the two
studies: Yamasaki et al. included a high number of patients
with elective involvement of optic nerve and spinal cord
while we considered only patients showing disseminate
central nervous system involvement [8]. Then Berg et al.
suggested a role of prolactin in the autoimmune process
reporting a relationship between reduction of MRI activity
and decline of PRL level after a single intravenous infusion
of methylprednisolone [9], while Nociti et al. reported a case
in which the relapses were triggered by hyperprolactinemia
[15]. Unfortunately, longitudinal data are not available in the
present study: a study on PRL fluctuations prior to, during,
and after a relapse could clarify if PRL may trigger disease
exacerbation rather than reflect an inflammatory status.
Secondly, we showed a positive correlation betweenwhite
matter volume and PRL in patients suffering from MS. The
role of PRL in WM regeneration and repair has been already
reported in experimental studies [2, 16, 17] and our data
reinforce this idea in clinical setting. Furthermore, PRL acts
as protective factor for WM atrophy but not for GM atrophy,
suggesting a specific role of PRL in development of WM
and in repair of MS damage. This observation is in line
with studies indicating a primary involvement of PRL in the
regulation of oligodendrocytes production [2, 16]. Gregg et
al. demonstrated an increase in oligodendrocytes precursor
cells proliferation and oligodendrocytes generation in the
maternal CNS and demonstrated that the increased genera-
tion of oligodendrocytes during pregnancy is associated with
an enhanced capacity to repair demyelination in thematernal
central nervous system [16]. A positive effect of PRL on
disease course has been also suggested from Zhornitsky et
al. [18]. The authors reported that prolactin associated with
recombinant murine interferon-𝛽 reduced severity of EAE
compared to PRL alone or to vehicle controls and reduced
spinal cord damage in treatedmice. Further studies in clinical
settings could be useful to study if PRL level is modified
during interferon therapy and if this modification is related
with clinical response to treatment.
Whether PRL levels are increased in MS patients is still
an open question. The lack of a control group of healthy
subjects does not allow us to answer this question; however,
we did not find a high prevalence of patients with PRL
levels above LNR in our population. In a recent review
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of literature, Zhornitsky et al. [14] suggested that PRL is
elevated in some MS patients, likely due to nonspecific
dysregulation of the hypothalamic-pituitary-adrenal (HPA)
axis, as a result of demyelination. Kira et al. [19] reported
the presence of hypothalamic lesions in patients suffering
frombothMS and hyperprolactinemia: the authors suggested
that the increase of serum prolactin may be considered to
be a sensitive indicator for hypothalamic lesions in MS.
Yamasaki et al. showed that hyperprolactinemia may be one
of the characteristic features of patients with MS who pref-
erentially show the optic nerve involvement and discussed
the possibility that location of damage could be crucial in
the development of hyperprolactinemia associated with MS
[8]. More sophisticated MRI studies considering regional
damage could help to clarify if the increase of PRL levels
reflects an impairment of specific structures rather than
progress of inflammation. Furthermore, to better clarify the
relationship between PRL and mechanisms of damage and
repair, measures of PRL levels in cerebrospinal fluid (CSF)
and production of PRLwithin the CNS should be considered.
Finally a recent case report from Watad et al. [20] raises
the question if whatever treats hyperprolactinemia in patients
with prolactinoma may prevent the development of auto-
immune diseases. We did not observe differences in MRI
activity, WM, and GM volumes in patients with PRL levels
above LNR compared with the others; however, due to the
low number of those patients (5 patients) we cannot exclude
a role of PRL in this specific population.
Some important caveats need to be considered in dis-
cussing our data. As mentioned above, the major limitation
of the study is the lack of a comparison with a population
of healthy controls and with a population suffering from
a clinical relapse. As another limitation of our study, we
could not investigate association of PRL levels with other
autoimmune or reproductive system pathologies in MS; in
fact, we excluded women suffering from MS in association
with other diseases.
Furthermore, the lack of a complete study of theHPA axis
limits the interpretation of the results. Overall, our study did
not support a role of PRL in subclinical disease activity as
detected by MRI, while the positive association of PRL levels
with WM volume suggests an involvement of PRL in WM
regeneration and repair. Further MRI studies with higher
fieldMRI andmore sophisticated analysis of regional damage
could help to understand complex role of PRL in MS.
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